drugset
drugset / Trial / NCT06165965

To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008

NCT06165965 ↗

Phase 1 Completed 48 enrolled Jeil Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the safety and pharmacokinetic characteristics after the administration of JT-001, JT-002 and JLP-2008

Timeline

Start
2022-05-03
Primary completion
2022-06-13
Completion
2022-06-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Subject JLP-2008 Unknown — Oral
Subject Pioglitazone Small molecule 15 mg Oral

Indications

No indication recorded.